The mechanism by which clonidine suppresses renin release was investigated in conscious rats. This suppression was studied by means of selected autonomic interventions in conjunction with changes in sodium balance. Serum renin activity and direct arterial pressure were monitored.
THE LOWERING of blood pressure by clonidine is accompanied by bradycardia and decreased activation of peripheral sympathetic nerves by the cardiovascular control center in the central nervous system. 1 These effects of clonidine appear to be mediated by stimulation of a-adrenergic receptors 2 ' 3 located in the vasomotor centers of the medulla oblongata. 3 -*"' Unlike many other hypotensive agents, clonidine suppresses renin release in man 8 -9 and in animals. 10 " 12 The purposes of this study were (1) to determine whether clonidine suppresses renin release by a site of action in the central or a peripheral nervous system, and (2) to characterize pharmacologically the mechanism by which this suppression occurs. Ganglionic, sympathetic neuron, and adrenergic receptor blocking agents were used in conjunction with altered states of sodium balance to localize and characterize this mechanism for inhibition of renin release. The conscious rat was used for these studies because of its relevance to physiological and pharmacological studies of the renin-angiotensin-aldosterone axis. 12 " 19 
Methods
We used 564 male Wistar rats (200-300 g) (Simonsen Laboratories) for these studies. They were housed in individual cages and exposed to light by an automated system from 6 a.m. to 6 p.m. The rats were given, ad libitum, tap water and Purina rat chow containing 152 mEq of sodium per kilogram. In some of the rats sodium depletion was achieved by substituting a sodium-deficient diet (Nutritional Biochemical) containing 40 mEq of sodium per kilogram for 5 days and giving furosemide (10 mg/kg, ip) during the first 3 days of dietary alteration.
Rats were decapitated and arterial blood was collected from the trunk as previously described. 13 Serum renin activity (SRA) was measured by the radioimmunoassay of angiotensin I generated in vitro at 37°C as previously described, 13 but with several modifications. 19 The serum sample from each rat was assayed in triplicate, and the average of these three determinations was used to calculate the mean ± SEM of the SRA values for each group of six rats receiving treatment with a particular drug. All experiments requiring the determination of SRA were terminated by decapitation at the times indicated in the figures and tables.
Clonidine, methoxamine, hydralazine, furosemide, phenoxybenzamine, and ketamine were administered intraperitoneally in 0.9% saline or 5% dextrose solution. The dextrose solution was used only for sodium-depleted rats. Phentolamine, clozapine, atropine, guanethidine, and chlorisondamine were administered subcutaneously in saline or dextrose solution. To prevent the acute effects of guanethidineinduced norepinephrine release, this drug was given on the day before and again 2 hours prior to the clonidine experiment. Clozapine was dissolved in 0.08 M HC1 and administered subcutaneously. Control animals were given an equal volume of 0.9% saline, 5% dextrose, or 0.08 M HC1 by the appropriate route. The dose of clonidine used for each experiment was 150 Mg/kg unless otherwise noted. All blocking drugs were given at a dose of 10 mg/kg except phenoxybenzamine (15 mg/kg) and clozapine (20 mg/kg) .
Direct measurement of mean arterial pressure (MAP) and heart rate in the unrestrained rat was made by minor modification of an automatically cycling blood pressure device described by Laffan and co-workers 20 and Weeks. 21 Direct MAP was measured from an indwelling Weeks' -i 50 f 30 z catheter which had been placed in the abdominal aorta 21 -22 at least 5 days before the experiment. Rats were free to move about in individual cages with the catheter connected to a Narco RP-1500 pressure transducer, a no. 7172 strain gauge coupler, and a DMP-4B Physiograph. For studies on hemodynamics, rats were used for only one experiment as illustrated in each figure.
Results of studies on SRA and blood pressure are reported in the same figure (e.g., Figs. 4 and 5), but separate groups of rats were used for these measurements. Blood pressures were measured in the same rats at different times after drug administration, whereas different groups of rats were used at each time for the measurement of SRA.
Statistical analyses were performed by the unpaired Student's /-test.
Results

CLONIDINE SUPPRESSION OF RENIN RELEASE
Clonidine (150 ng/kg) lowered SRA by 85% within 10 minutes after intraperitoneal administration to normal conscious rats (Fig. 1) . In another group of rats, MAP was Sodium-depleted control (5% dextrose 20.5 ± 3.2 in water)* Clonidine (150pg/kg) 6.0 ± 0.7J Propranolol (1.5 mg/kg) 14.0 ± 1.5 Propranolol, then clonidine 8. 5 ± 2.2f Propranolol was given 10 minutes prior to clonidine, and blood was collected 20 minutes after clonidine. Control, clonidine-treated, and propranolol-treated rats were killed 20, 20, and 30 minutes postinjection, respectively. Each value is the mean ± SEM for six animals. P values are a comparison between the treated groups and the control.
1-I-
• Serum renin activity in normal sodium controls = 2.6 ± 0.6 ng angiotensin I (Ai)/ml per hr.
tP < 0.01. \P < 0.001. elevated temporarily (14.3% increase) by clonidine. However, MAP had returned to control levels within 40 minutes and to hypotensive levels (12.5% decrease) at 100 minutes, at which time SRA still was suppressed (65% decrease). Thus, clonidine altered the usual reciprocal relationship between SRA and MAP at times greater than 40 minutes after administration. Suppression of SRA (53% of control value, P < 0.05) by clonidine occurred at doses as low as 30 jig/kg (Fig. 2) , and increasing the dose up to 1 mg/kg resulted in further suppression of SRA.
We evaluated the possibility that inhibition of the renin enzyme might have caused this rapid fall of SRA after clonidine. Clonidine was added to incubations in vitro of pooled rat serum in concentrations of 10~6, 10~5, and 10~4 M; this did not alter production of angiotensin I. Also, renin was injected intravenously into anesthetized rats before and after clonidine (150 Mg/kg. >P) while MAP was measured. The pressor response to renin was not altered by clonidine administration, indicating that renin-inhibiting substances were not released or formed in vivo. Thus, the fall of SRA after clonidine appears to be due to inhibition of renin release mechanism(s) per se.
EFFECT OF CLONIDINE AND PROPRANOLOL ON RENIN RELEASE INDUCED BY SODIUM DEPLETION
Sodium depletion caused by the restriction of dietary sodium and the administration of furosemide resulted in an 8-fold elevation of SRA, and this sodium-volume stimulus to renin release was inhibited by 71 % by clonidine (Table 1) . Propranolol (1.5 mg/kg), in a dose that blocks 91% of /8-adrenergically mediated renin release," did not lower SRA significantly (30% decrease) ( Table 1 ). In addition, propranolol pretreatment did not prevent clonidine from suppressing SRA (60% decrease). Thus, clonidine appears to suppress renin release through a mechanism different from /9-adrenergic blockade.
THE EFFECT OF GANGLIONIC AND SYMPATHETIC NEURON BLOCKADE ON SUPPRESSION OF RENIN RELEASE BY CLONIDINE
These studies were designed to block neural connections between the central nervous system and the kidney in the 
FIGURE 3
Effect of clonidine on renin release induced by sodium depletion and its modification by autonomic blockers. Chlorisondamine, phentolamine, and clozapine were administered 20 minutes before clonidine, and blood was collected 20 minutes after clonidine. Guanethidine was administered 24 and 2 hours before clonidine, and blood was collected 20 minutes after clonidine. The guanethidine control animals were killed 140 minutes after the last dose of guanethidine. Animals receiving only chlorisondamine, phentolamine, or clozapine were killed at 40 minutes postinjeclion. Control and clonidine-lreated rats were killed at 20 minutes poslinjection. Statistical comparisons are between the various treatment groups and the control value. Each value is the mean ± SEM for six animals.
presence and absence of a sodium depletion stimulus to renin release. Neither the sympathetic neuronal blocking drug, guanethidine, nor the ganglionic blocking drug, chlorisondamine, mitigated inhibition of renin release by clonidine in sodium-depleted rats ( Fig. 3 ), as indicated by suppression of renin release by clonidine even in the presence of these blocking drugs (75% and 66%, respectively, P < 0.01).
We made further studies on ganglionic blockade in normal sodium rats in which chlorisondamine and atropine were combined (Table 2) in order to block simultaneously both nicotinic and muscarinic receptors in sympathetic ganglia. In face of this total ganglionic blockade, clonidine still suppressed renin release by 75% (P < 0.05) ( Table 2) . Atropine alone had no effect on this action of clonidine in normal rats (74% decrease, P < 0.05) ( Table 2 ). These results for low sodium and normal sodium rats indicate that clonidine did not suppress renin release by a central site of action and imply an effect of clonidine peripheral to the sympathetic neuron.
a-ADRENERGIC BLOCKING DRUGS AND SUPPRESSION OF RENIN RELEASE BY CLONIDINE
The a-adrenergic receptor blocking drugs, phenoxybenzamine and phentolamine, inhibited the ability of clonidine to suppress renin release in sodium-depleted animals ( Table 3 and Fig. 3 , respectively). Likewise, clozapine, a neuroleptic agent that possesses a-adrenergic blocking activity, 2 3-" prevented the effect of clonidine on renin release in sodiumdepleted rats (Fig. 3 ). This evidence, combined with the observations made during sympathetic neuron and ganglionic blockade ( Fig. 3 ), suggests that clonidine suppresses renin release by stimulation of peripheral a-adrenergic receptors.
Additional support for an a-receptor mechanism was obtained from rats in normal sodium balance. In normal rats phentolamine only partially blocked suppression of renin release by clonidine. The chronology of this response is shown in Figure 4 . Clonidine suppressed renin release (80% of phentolamine control at 30 minutes) in rats pretreated with phentolamine, and this response occurred in the presence of hypotension (MAP decreased by 27%). Phentolamine blocked the initial pressor effect of clonidine and potentiated the later depressor phase. Clonidine alone caused a 12.5% decrease in blood pressure at 100 minutes ( Fig. 1) , whereas phentolamine and then clonidine elicited a 27% decrease in MAP at 20 minutes (post-clonidine) and a 20% decrease at 100 minutes ( Fig. 4 ). However, it should be noted that phentolamine itself already had lowered MAP by 17% by the time clonidine was administered. This hypotensive effect probably plays a role in the stimulation of renin release caused by phentolamine. 25 Clozapine prevented clonidine suppression of renin release in normal rats ( Fig. 5 ). Again, the initial pressor phase after clonidine was eliminated. Clozapine had lowered blood pressure by 5% at the time clonidine was given and did not greatly potentiate (18% decrease in MAP at 100 minutes) the hypotensive effects of clonidine. Phenoxybenzamine also blocked clonidine suppression of renin release in normal rats (Table 3) . Thus, clozapine, an agent with a-adrenergic Atropine and chlorisondamine or atropine alone were given 10 minutes prior to clonidine. and blood was collected 20 minutes after clonidine. Control, clonidine-treated, and blocker-treated rats were killed at 20. 20. and 30 minutes postinjeclion, respectively. Each value is the mean ± SEM for six animals. Ai = angiotensin I. P values are a comparison of the treated groups with the control. * P < 0.05. t/> < 0.01. 3.93 ± 1.09t 190.00 ± 9.6t 203.57 ± 33.05t NS Phenoxybenzamine was given 60 minutes prior to clonidine, and blood was collected 20 minutes after clonidine. Control, clonidine-treated, and phenoxybenzamine-treated rats were killed at 20, 20, and 80 minutes postinjection, respectively.
Each value is the mean ± SE.M for six animals. P values are a comparison between the treated groups and the control group. NS indicates that the difference between the values in the last two columns is not significant at the P < 0.05 level. D5W = 5% dextrose in water.
*P < 0.01. tf < 0.001. blocking properties, 23 -" and phenoxybenzamine blocked suppression of renin release under all conditions studied (Figs. 3 and 5, Table 3 ).
EFFECTS OF CLONIDINE ON /3-ADRENERGICALLY STIMULATED RENIN RELEASE
We studied the ability of clonidine to suppress renin release caused by activity of sympathetic neurons by administering ketamine and hydralazine. Ketamine, an anesthetic agent with a mild pressor effect, induces renin release through a sympathetic nervous system mechanism that ultimately involves activation of /9-adrenergic receptors. 26 Alternatively, hydralazine lowers blood pressure while inducing renin release through a /8-adrenergic mechanism. 19 Clonidine inhibited ketamine-and hydralazine-induced renin release by 90% and 64%, respectively ( Table  1 ), but apparently by a-adrenergic stimulation which resulted in a pharmacological antagonism of ^-adrenergically mediated renin release.
HEMODYNAMIC-RENIN RELEASE CORRELATES DURING GANGLIONIC BLOCKADE
Because ganglionic blockade with chlorisondamine removes hemodynamic buffering mechanisms, it was possible that clonidine could have exerted a potentiated pressor effect under these circumstances and suppressed SRA by an intrarenal baroreceptor mechanism. 27 -28 Indeed, it was found that pretreatment with chlorisondamine 10 minutes before administration of clonidine did potentiate the initial pressor response to clonidine in sodium-depleted rats (results not shown). Clonidine elevated MAP by 35% (at 20 minutes) above the control value in sodium-depleted rats, compared to an increase of 14% at the same time in normal rats ( Fig. 1 ). After chlorisondamine, which decreased MAP by 37% (at 10 minutes), clonidine increased MAP by 51% (at 20 minutes) above the initial control value.
Since the marked elevation of blood pressure by clonidine administration after chlorisondamine (MAP = 160 mm Hg at 20 minutes) could have altered renin release, samples for renin were taken 60 minutes after clonidine when blood pressure had stabilized at control levels (results not shown). At this time, clonidine suppression of renin release was highly significant (Table 5) , even though blood pressure had returned to control values. Therefore, the pressor effect of clonidine was not necessary for this drug to suppress renin release during ganglionic blockade. These data indicate that the site of action of clonidine is peripheral to the central nervous system and not necessarily dependent on changes in systemic blood pressure.
To test further the hypothesis that clonidine suppresses renin release by stimulating a peripheral a-adrenergic receptor, we administered both chlorisondamine and phentolamine before clonidine (Table 6 ). Again, blood was sampled 60 minutes after the clonidine injection to ensure that systemic hemodynamic changes were not a factor. Clonidine decreased basal SRA by 83% at 60 minutes and phentolamine alone increased renin by 270% (70 minutes). Chlorisondamine and phentolamine together caused an increase of nearly 400% in SRA, and clonidine decreased this value by 30% (/>, not significant) ( Table 6 ). With ganglionic blockade alone (Table 5) , SRA was elevated to 240% of the control and clonidine decreased this value by 90%. Thus, the major fraction of the renin suppression caused by clonidine in sodium-depleted, ganglion-blocked rats could be blocked by phentolamine. These data also support the view that clonidine suppression of renin release is mediated via an a-adrenergic receptor apparently located in the kidney vasculature or juxtaglomerular cells.
COMPARISON OF THE ABILITY OF CLONIDINE OR METHOXAMINE TO SUPPRESS RENIN RELEASE IN SODIUM-DEPLETED, GANGLION-BLOCKED RATS
Methoxamine (10 mg/kg), administered 10 minutes after ganglionic blockade with chlorisondamine in sodium-depleted rats, elicited an increase in blood pressure (MAP = 167 =t 5 mm Hg at 20 minutes) similar to that occurring after clonidine (150 /ig/kg). These equipressor doses of clonidine and methoxamine were compared with respect to their ability to suppress renin release in the presence and absence of ganglionic blockade (Fig. 6 ). In the absence of ganglionic blockade, clonidine and methoxamine suppressed SRA by 84% and 43%, respectively, with clonidine having a significantly greater effect (P < 0.05) than methoxamine (Fig. 6 ). In the presence of ganglionic blockade, clonidine and methoxamine lowered SRA by 76% and 54%, respectively, with clonidine again having a greater effect (P < 0.05) than methoxamine (Fig. 6) . These results suggest that while both agents have the property of being a-adrenergic receptor agonists, clonidine has a higher specificity for, or lonidine was given 20 minutes prior to hydralazine or ketamine, and blood was collected 20 minutes after hydralazine or ketamine. Control, clonidine-treated, hydralazine-treated, and ketamine-treated rats were killed at 20, 40, 20, and 20 minutes postinjection, respectively. Each value is the mean ± SEM for six animals. P values are a comparison between the treated groups and the control groups. Ai = angiotensin I.
•/> < 0.001. IP < 0.01. more selective distribution to, the a-adrenergic receptors within the kidney that control renin release.
Discussion
At least four mechanisms are known to alter renin release: (1) a renal baroreceptor that is responsive to changes in renal perfusion pressure, 27 ' 2S (2) a sodium-sensing mechanism in the macula densa segment of the distal tubule, 29 ' 30 (3) the sympathetic nervous system, 31 and (4) angiotensin-II per se. s2 -"
The first two mechanisms, which maintain an inverse relationship between renin release and sodium-volume balance, are combined in this discussion because they cannot be distinguished by the techniques used here. The third mechanism is stimulatory to renin release and is mediated by /3-adrenergic receptor activation. 31 It can be blocked and quantified with the use of propranolol. 15 ' 19 ' 25 Examples of the effect of this mechanism on renin release are seen during upright posture 34 and after administration of vasodilating drugs 19 and ketamine. 29 The fourth mechanism is an angiotensin-mediated negative feedback suppression of renin release 32 -33 that can be blocked by an angiotensin antagonist. 35 This short-loop system feeds into a control Chlorisondamine was given 10 minutes prior to clonidine and blood was collected 60 minutes after clonidine. Control, clonidine-treated, and chlorisondamine-treated rats were killed at 50, 60, and 70 minutes postinjection, respectively. Each value is the mean ± SEM for six animals. P values are a comparison between the treated groups and the control group.
•Serum renin activity in normal sodium controls = 1.8 ± 0. Phentolamine and chlorisondamine were given 10 minutes prior to clonidine, and blood was collected 60 minutes after clonidine. Control, clonidine-treated, phentolamine-treated, and chlorisondamine-plus phentolamine-treated rats were killed at 60, 60, 20, and 70 minutes postinjection, respectively. Each value is the mean ± SEM for six animals. P values are a comparison between the treated groups and the controls. NS indicates that the difference between the two bracketed values is not significant at the P < 0.05 level.
• Serum renin activity in normal sodium controls = 2.3 ± 0.5 ng A,/ml per hour. t/> < 0.001. J P < 0.05. %P < 0.01. mechanism functionally located proximal to the /3-adrenergic receptor, since it can be blocked by propranolol. 35 Drugs that alter renin release can act by one or more of these mechanisms or possibly by one yet to be defined. Clonidine lowers blood pressure, heart rate, and cardiac output by an action in the brain that results in depression of peripheral sympathetic neuronal activity (see introductory section). The first problem in the study of the site and mechanism of action of clonidine was to determine whether clonidine suppresses renin release by an effect on the central nervous system. Chlorisondamine or atropine, or both, as ganglionic and parasympathetic blocking agents, and guanethidine, as a sympathetic neuron-blocking drug, failed to prevent suppression of renin release by clonidine. Since ganglionic blockade prevents the indirect, peripheral cardiovascular effects of clonidine, 36 clonidine must suppress renin by a direct action at a peripheral site. The inability of these drugs to block this effect of clonidine indicates that its site of action is not located proximal to or within peripheral autonomic neurons.
Impairment of the effect of clonidine by phenoxybenzamine (Table 3) , phentolamine ( Figs. 3 and 4) , and clozappine ( Figs. 3 and 5) , indicates that adrenergic receptors of the a type mediate this effect. The question then is whether the a-receptors involved are in the peripheral vasculature or in the kidney. Clonidine temporarily increases blood pressure when given parenterally, and this pressor action can be prevented by a-receptor-blocking drugs. This increase in blood pressure, by activation of the intrarenal baroreceptors, could be implicated as a mechanism for at least part of the effect of clonidine on renin secretion. However, blood pressure was below control levels at times when clonidine was suppressing renin release (Fig. 1) . Forty minutes after clonidine had been administered to normal sodium rats, blood pressure had returned to control levels.
Blood pressure subsequently declined to hypotensive levels and renin release was suppressed throughout this period. Thus clonidine does not lower SRA by a peripheral pressorintrarenal baroreceptor mechanism but rather by a direct intrarenal action.
Following chlorisondamine administration to sodiumdepleted rats, clonidine elevated blood pressure to a greater extent than it did in the absence of ganglionic blockade. Under these circumstances, part of the suppression of renin release by clonidine could be ascribed to vasoconstrictormediated activation of the intrarenal baroreceptor mechanism. However, 1 hour after administration of clonidine, blood pressure had returned to control levels and at this time clonidine continued to suppress renin release (90% decrease) ( Table 5 ) to the same extent (68% decrease) ( Fig. 3) as when blood pressure was elevated at 20 minutes. Therefore, I hour after drug administration the peripheral pressor effect of clonidine is not the mechanism that suppresses renin release, and an intrarenal site of action is implicated. Since this effect of clonidine can be blocked by administration of phentolamine during ganglionic blockade (Table 6) , an intrarenal adrenergic receptor of the a type is implicated in the suppression of renin by clonidine.
The a-adrenergic-blocking drugs phenoxybenzamine, phentolamine, and clozapine inhibited suppression of renin release by clonidine 6 Comparison of the ability of methoxamine or clonidine to suppress serum renin activity (SRA) in sodium-depleted animals in the presence and absence of ganglionic blockade with chlorisondamine. Chlorisondamine was administered 10 minutes before methoxamine or clonidine, and blood was collected 20 minutes after clonidine or methoxamine. Control, clonidine-treated, methoxamine-treated, and chlorisondamine-trealed animals were killed at 20, 20, 20, and 30 minutes postinjeclion, respectively . P values are given in the middle of the line connecting the two groups compared. Each value represents the mean ± SEM for six animals. VOL. 38, No. 5, MAY 1976 exception of the limited efficacy of phentolamine in normal sodium rats (Fig. 4) . The reason for this differential effect of phentolamine in normal vs. sodium-depleted rats is not clear at this time. When clozapine is administered peripherally, it enters the brain and blocks central norepinephrine receptors, as indicated by an increase in norepinephrine turnover, an effect that is opposed by clonidine. 37 Since clozapine has ready access to the central nervous system, the ability of clozapine to block the effects of clonidine on renin secretion does not distinguish between a central or a peripheral site of action for clonidine.
Clonidine induces a temporary blood pressure elevation by directly activating peripheral a-adrenergic receptors. Later clonidine decreases blood pressure by suppressing peripheral sympathetic discharge. Phentolamine pretreatment eliminates this temporary adrenergic vasoconstriction by blocking a-receptors. Both drugs lower pressure by an action at different sites, but the ultimate effect is the same, i.e., a decrease in a-adrenergic vasoconstriction. Thus, when given together the two drugs would be expected to exhibit an enhanced hypotensive effect, as compared to clonidine alone (Fig. 1) , and this indeed is the case (Fig. 4) . The blood pressure decrement after administration of clozapine plus clonidine is probably due to the peripheral a-adrenergic blocking properties of clozapine alone, since clozapine and clonidine have opposing actions at central norepinephrine receptors. 37 Further evidence against a baroreceptor-vascular effect of clonidine as the primary mechanism of altering renin release has been provided by Onesti et al., 9 using anesthetized dogs. These investigators found a similar biphasic blood pressure change (as in Fig. 1) accompanied by a 17.2% decrease in renal vascular resistance and a 50% suppression of renin release. Thus, renal vasodilation rather than vasoconstriction was present while renin release was suppressed. In addition, we have demonstrated that clonidine can prevent renin release that is accompanied by either an increase (ketamine) or a decrease (hydralazine) in blood pressure (Table 4) .
A mechanism involving the macula densa also is doubtful. Sodium retention has been reported to accompany the use of clonidine. 9 However, when administered acutely, it seems doubtful that this mechanism could expand extracellular fluid volume so rapidly that suppression of renin release (by 70-90%) could occur within 10 minutes (Fig. 1) . This acute sodium retention would result in less sodium being presented to the macula densa, an event that would be expected to increase renin release rather than decrease it. 29 In addition, in severe sodium depletion, when sodium-retaining mechanisms are functioning at a high level, clonidine still suppresses renin release (Fig. 3 ). For these reasons clonidine does not appear to be acting through the macula densa mechanism to suppress renin release.
Yun and co-workers 38 ' 39 have suggested that vagal influence on the kidney alters renin release. Even though clonidine has been found to induce bradycardia by vagal activation, 40 its action on renin release appears to be independent of the parasympathetic nervous system since atropine or chlorisondamine, or both, did not alter its action ( Table 2) .
Clonidine suppressed normal renin release ( Fig. 1) and that induced by a low sodium diet and a diuretic agent (e.g., Fig. 3 ). Propranolol was much less effective (Table 1) in suppressing this physiological type of renin release, indicating that it is not mediated predominantly through the sympathetic neuron-/3-adrenergic receptor mechanism. The remarkable capacity of clonidine to suppress renin release under these circumstances suggests that it is acting on a renin release-governing mechanism that is independent of, or functionally distal to, the /3-adrenergic receptor mechanism.
An a-adrenergic mechanism inhibitory to renin release was previously suggested by studies in conscious rats given isoproterenol, epinephrine, and norepinephrine intraperitoneally." Isoproterenol induced a characteristic dose-related increase in SRA. Epinephrine was less effective, and at higher doses SRA had decreased to control values. Norepinephrine was an effective (85% of control) suppressor of renin release in low doses, whereas high doses tended to increase SRA back to control levels. These early studies were limited by the fact that the patterns of renin release obtained could be explained partly on the basis of peripheral blood pressure changes which, in turn, could alter the intrarenal baroreceptor stimulus to renin release. Through studies on the isolated, perfused rat kidney, Vandongen and Peart 41 more recently have found that the a-adrenergic agonist methoxamine prevented isoproterenolinduced renin release.
The precise anatomical location of this receptor is unknown. Arguments in favor of a postsynaptic location are (1) clonidine can activate postsynaptic a-adrenergic receptors, 1 -2| ' and (2) clonidine suppresses renin release even when peripheral sympathetic neurons are nonfunctional as a result of the administration of ganglionic or sympathetic neuron-blocking drugs. Evidence consistent with a presynaptic site is (1) clonidine can activate presynaptic a-adrenergic receptors which are inhibitory to norepinephrine release, 1 and (2) phentolamine induces renin release which is blocked by propranolol. 25 Blockade of presynaptic a-adrenergic receptors by phentolamine could cause overflow of transmitter norepinephrine. Since postsynaptic a-adrenergic receptors also would be blocked, the excess quantity of norepinephrine would activate /J-adrenergic receptors which are known to be stimulatory to renin release. 18 ' 19 ' "• "• 31 This 0-adrenergic mediated renin release would be unopposed by the inhibitory a-adrenergic receptor and thus result in release of large quantities of renin, as seen in Figures 3  and 4 and Table 6 . We favor a postsynaptic site for the a-adrenergic receptors inhibitory to renin release, but under certain circumstances presynaptic a-adrenergic receptors may contribute to alteration of renin release. These inhibitory receptors may be located either on vascular or juxtaglomerular cells, or on both.
There are interesting similarities between receptor mechanisms altering renin release and receptors altering peripheral vascular tone. Juxtaglomerular cells are modified smooth muscle cells 42 and thus could possess a-adrenergic receptors similar to those found on arteriolar smooth muscle membranes. Since clonidine, like norepinephrine, contracts vascular smooth muscle by a-adrenergic receptor stimulation, 43 it is conceivable that this drug would have a similar action on juxtaglomerular cell a-receptors. Similarly, angi-otensin contracts vascular smooth muscle and can directly inhibit renin release by an action independent of its systemic hemodynamic effects. 32 -33 Blockade of angiotensin receptors by saralasin, a selective angiotensin antagonist, removes this inhibitory influence and induces renin release, which in turn can be blocked by propranolol. 3 ' Alleviation of a-adrenergic inhibition by phentolamine also results in renin release which can be blocked by propranolol. 25 Simultaneous blockade of these two inhibitory mechanisms by phentolamine and saralasin results in release of remarkable quantities of renin,* 4 which release, again, can be blocked by propranolol pretreatment (unpublished observation). Thus, angiotensin and norepinephrine receptors of the smooth muscle-derived juxtaglomerular apparatus may be functionally similar.
There may be reason to believe, however, that there are differences in drug access to vasoconstrictor receptors in vascular smooth muscle as compared to these same receptors in the juxtaglomerular apparatus. Recent observations by Reid and co-workers 45 and from our own laboratory (unpublished observations) have suggested the possibility that polar substances like isoproterenol may not have ready access to the intrarenal /8-receptor mediating renin release. Reid et al. have shown that isoproterenol is as effective in inducing renin release when administered by systemic vein as when given in the renal artery. In face of overwhelming evidence for an intrarenal /3-receptor mechanism mediating renin release,"-28 ' "• "• 34 -41 -4! one must postulate impaired access of isoproterenol to these /8-receptors in order to explain these interesting findings.
Results of studies with methoxamine, an a-adrenergic receptor agonist, are consistent with this hypothesis. When clonidine and methoxamine were administered in equipressor doses with or without ganglionic blockade, clonidine was more effective in suppressing renin release than methoxamine. Because of its lipid solubility, clonidine may penetrate more readily into the intrarenal site of this inhibitory receptor governing renin release. Alternatively, clonidine may have a higher degree of "specificity" for the intrarenal a-adrenergic receptor than agents such as methoxamine or even norepinephrine.
One could propose a functional lipid membrane encompassing the sympathetic neuron-juxtaglomerular apparatus. Such a membrane, which may be represented by the axon-Schwann cell complex that has been reported to extend at least to the terminal portion of the sympathetic neuron in the vicinity of the juxtaglomerular cells, 4 * could be used to explain the greater effectiveness of phenoxybenzamine or clozapine as opposed to phentolamine in blocking clonidine suppression of renin release. Phentolamine has limited access to brain tissue, 3 whereas phenoxybenzamine' and clozapine, 37 by virtue of their lipid solubility, readily cross the blood-brain barrier. Likewise, clonidine is lipid-soluble at pH 7.4 and would be expected to have ready access to intrarenal a-receptors of the juxtaglomerular apparatus.
Alternatively, norepinephrine is a polar substance at pH 7.4 and, unless released by nerve stimulation, would have limited access to these receptors. Likewise, methoxamine has limited lipid solubility. Thus, exogenously administered or circulating norepinephrine (or methoxamine) would be expected to have a high degree of specificity for vascular a-receptors to which they are more efficiently distributed.
On the other hand, clonidine would appear to have more "specificity" for a-adrenergic inhibitory receptors in the cardiovascular control center of the brain and in the juxtaglomerular apparatus of the kidney. However, norepinephrine may have a high degree of "specificity" for vascular receptors by virtue of its exclusion from these latter two sites. In this respect it is interesting that centrally administered norepinephrine lowers blood pressure as does clonidine. 1 Additional biochemical studies are needed to further test this hypothesis.
Recently, methoxamine, in a dose that caused a 12% increase in MAP, was reported to elicit a 100% increase in plasma renin activity in healthy humans. 47 In the experiments reported here, methoxamine consistently decreased SRA. However, it is possible that methoxamine could mildly stimulate renin release at very low doses and inhibit it at high doses, a pattern previously reported for epinephrine in rats. 25 Recent findings with methoxamine in an in vitro system are consistent with this speculation. Methoxamine induced the release of renin from renal tissue slices, and this effect was blocked by propranolol but not by phentolamine. 48 These data indicate that methoxamine can act as a partial agonist at the /}-adrenergic receptor controlling renin release. 48 Methyldopa lowers blood pressure and SRA in hypertensive man 49 -50 and in anesthetized dogs. 51 Consistent with the hypothesis presented here, methyldopa, by virtue of its amino acid structure, is readily transported into the central nervous system by an amino acid pump. The metabolites methyldopamine and methylnorepinephrine are formed in the brain. Like clonidine, these compounds have a-adrenergic agonist activity and are believed to lower blood pressure by this action. 1 In a similar fashion they could activate intrarenal a-adrenergic receptors inhibitory to renin release.
Reid and colleagues 11 have proposed a central nervous system site of action for clonidine suppression of renin release. Their experiments were conducted in dogs given anesthetic agents that alter renin release mechanisms per s e i3. is. 31 T n e j r conclusions were based on (1) the ability of clonidine (1 /ig/kg) to suppress renin release when injected into the 3rd ventricle (brain) of dogs, and (2) the failure of intravenously administered clonidine (30 fig/kg ) to suppress renin release in unilateral, denervated kidneys in vivo. However, the capacity of intraventricular clonidine to suppress SRA could not be demonstrated unless aortic clamping > was used. In addition, renin release from the denervated kidneys had dropped to almost zero before clonidine was given intravenously, and the drug would not be expected to further depress renin release from these kidneys by any mechanism. Therefore, a peripheral site of action for clonidine could not be excluded by their studies. Alternatively, the data reported here do not exclude a central site of action for clonidine in drug-free animals. They do, however, provide evidence suggesting intrarenal a-adrenergic receptors which are inhibitory to renin release.
